RxDoctor Payments Data

Sujoya Dey, MD

Clinical Cardiac Electrophysiology · Larkspur, CANPI 1003934449

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $26,625 of the $33,890 with a category attached, or 78.6%. Medical Device Business Services, Inc. accounts for 78.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $14,032 and has fallen 91.3% since, to $1,218 in 2025.

$33,890in general payments, 2019–2025

Across 214 payments — averaging $158.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$27K
  • Abbott$3K
  • Medtronic$2K
  • Boston Scientific$2K
  • Biosense Webster, Inc.$268
  • Edwards Lifesciences$172
  • plus $411 from 11 others

What the payments were for

  • Consulting fees$26,62579%
  • Travel & lodging$1,4264%
  • Food & beverage$5,83917%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,890 in reported general payments places this provider in the 55th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California →

Medicare billing

Part B allowed, 2024
$389,937
Medicare patients
907
Services billed
4,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$99,267
MultaqDronedarone Hcl54$54,906
XareltoRivaroxaban20$29,614
SotalolSotalol Hcl64$809
Digoxin29$610
Ranolazine ErRanolazine13$597
Amiodarone Hcl25$582
Metoprolol Succinate29$569
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$368
Metoprolol Tartrate38$348
Diltiazem Hcl17$253
Cephalexin45$242
Famotidine33$236
ClopidogrelClopidogrel Bisulfate18$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$36$29,61420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Larkspur

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →